Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + cisplatin
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
This therapeutic regimen consists of a combination of nab-paclitaxel and cisplatin administered through Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Developed and investigated by the Mayo Clinic, it is specifically targeted at patients with pancreatic cancer that has metastasized to the peritoneum. Nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel that promotes microtubule assembly and prevents disassembly, thereby arresting the cell cycle. Cisplatin is a platinum-based chemotherapeutic agent that forms inter- and intra-strand DNA cross-links, inhibiting DNA synthesis and inducing apoptosis. The HIPEC procedure involves the delivery of these agents in a heated solution directly into the abdominal cavity, which is intended to increase the local concentration of the drugs and enhance their cytotoxic effects against peritoneal tumor nodules.
- Brand names
- Abraxane + Platinol
- Other names
- HIPEC-nab-paclitaxel-cisplatinnab-paclitaxel and cisplatin
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + cisplatin.